QUÉBEC CITY, Aug. 28, 2013
/PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the
"Company") today announced that its request to transfer its listing
to the NASDAQ Capital Market® from the NASDAQ Global
Market® has been approved by the NASDAQ Listing
Qualifications Staff. The Company's securities will begin trading
on the NASDAQ Capital Market effective at the opening of trading on
Thursday, August 29, 2013. The
transfer of the Company's listing to the NASDAQ Capital Market is
not expected to have any impact on trading in the Company's shares,
and the Company's shares will continue to trade on NASDAQ under the
symbol AEZS and with the same CUSIP number of 007975303.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing novel treatments in oncology and
endocrinology. The Company's pipeline encompasses compounds from
drug discovery to regulatory approval. For more information, visit
www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbour provisions of the U.S. Securities
Litigation Reform Act of 1995, including forward-looking statements
relating to the expected impact of the transfer of the listing of
the Company's shares on the NASDAQ Capital Market. Forward-looking
statements involve known and unknown risks and uncertainties that
could cause the Company's actual results to differ materially from
those in the forward-looking statements. Such risks and
uncertainties include, among others, market reaction to the
transfer of the listing of the shares on the NASDAQ Capital Market,
the availability of funds and resources to pursue R&D projects,
the successful and timely completion of clinical studies, the risk
that safety and efficacy data from any of our Phase 3 trials
may not coincide with the data analyses from previously reported
Phase 1 and/or Phase 2 clinical trials, the ability of the
Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions.
Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to
update these forward-looking statements. We disclaim any obligation
to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained
herein to reflect future results, events or developments, unless
required to do so by a governmental authority or by applicable
law.
SOURCE Aeterna Zentaris Inc.